RA
DFTX

Royce & Associates’s Definium Therapeutics DFTX Stock Holding History

Royce & Associates’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.42M Buy
234,051
+70,010
+43% +$1.19M 0.04% 483
2025
Q4 		$2.2M Buy
164,041
+83,017
+102% +$1.03M 0.02% 579
2025
Q3 		$955K Buy
+81,024
New +$756K 0.01% 671

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Royce & Associates's DFTX Position: Q1 2026 in Review

Royce & Associates increased its Definium Therapeutics (DFTX) stake by 43% in Q1 2026, buying an estimated $1.19M and bringing the position to 234,051 shares worth $4.42M. The position accounts for 0.04% of the portfolio, ranked #483.

Royce & Associates first reported a position in DFTX in Q3 2025 and has held it in 3 quarters since. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • Royce & Associates held 234,051 shares of Definium Therapeutics worth $4.42M as of Q1 2026.
  • Royce & Associates bought 70,010 Definium Therapeutics shares in Q1 2026, an estimated $1.19M.
  • Definium Therapeutics made up 0.04% of Royce & Associates's portfolio in Q1 2026, its #483 holding.
  • Royce & Associates first reported a position in Definium Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on Royce & Associates's 13F filing for Q1 2026, filed 12 May 2026.